Survodutide

Survodutide, BI 456906, is a peptide glucagon/GLP-1 receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma. Published SYNCHRONIZE-1 and SYNCHRONIZE-2 results provide Phase 3 evidence beyond the earlier Phase 2 program.

Zealand’s October 2026 announcement describes it as investigational and not approved for use. A successful trial or development designation is separate from approval, a commercial launch date and a personal prescription.

Combined glucagon and GLP-1 receptor activity is the mechanistic rationale. SYNCHRONIZE-MASLD measured liver fat and weight; it does not prove every proposed organ-specific mechanism or quantify how much each receptor contributed.

These trials do not establish that a dual agonist is safer than a triple agonist, that it prevents cardiovascular events or that it is superior to another active medicine. Placebo-controlled weight and liver-fat findings should be described on their own terms.

SYNCHRONIZE-1 randomized 725 adults without diabetes. At 76 weeks, treatment-regimen mean weight changes were −12.2% at 3.6 mg and −13.0% at 6 mg versus −5.4% placebo.

SYNCHRONIZE-2 randomized 752 adults with type 2 diabetes. Corresponding 76-week treatment-regimen changes were −8.2%, −9.8% and −3.9%. HbA1c changes were −0.9 and −0.8 percentage points with active treatment versus −0.2 placebo, from a baseline of 7.4%.

The 216-person MASLD trial assessed 48 weeks. At least 30% relative liver-fat reduction occurred in 84.2% versus 24.3% with the efficacy estimand, and 68.5% versus 28.6% with the treatment-regimen estimand. These analyses answer different questions and should not be mixed into one headline.

The obesity and diabetes studies demonstrate favorable weight findings, with glycemic improvement in the diabetes population. The MASLD study provides a distinct liver-fat signal.

MRI liver-fat change is not the same as biopsy-confirmed fibrosis improvement, and improved biomarkers do not establish fewer heart attacks or strokes. Dedicated outcomes and longer follow-up remain separate questions.

The two 76-week obesity trials used once-weekly subcutaneous target amounts of 3.6 or 6 mg. The MASLD trial used a 6 mg target. These reports do not establish a generic 2–4 mg start followed by 6–10 mg maintenance or a 12–16-week standard course.

The development announcement is not a prescribing label. A trial protocol’s screening, escalation and monitoring cannot be replaced with a research-vial recipe; no guaranteed approval or launch year follows from the results.

In SYNCHRONIZE-1, gastrointestinal events occurred in 80.9% and 89.7% of active groups versus 47.9% placebo; no deaths were reported. In SYNCHRONIZE-2, gastrointestinal events occurred in 72.8% and 77.7% versus 38.6%, generally mild or moderate and transient.

Those findings do not support an invented 10–25% universal nausea profile or a blanket tolerability advantage over triple agonists. Study eligibility criteria and theoretical class risks are also different from the contraindications of an approved survodutide label.

Editorial update: October 27, 2026. Original indexed 2026 SYNCHRONIZE-1, SYNCHRONIZE-2 and MASLD abstracts and relevant parts of the October company announcement were read. The main company webpage was not text-accessible through the attempted route; not every full journal paper was obtained. Published treatment-regimen estimates are kept separate from other headline estimands. This is an editorial source check, not clinician review or a completed whole-family review. Read a key primary source.